PE20240235A1 - Compuesto de quinazolina para inducir la degradacion de la proteina kras mutante g12d - Google Patents
Compuesto de quinazolina para inducir la degradacion de la proteina kras mutante g12dInfo
- Publication number
- PE20240235A1 PE20240235A1 PE2023002366A PE2023002366A PE20240235A1 PE 20240235 A1 PE20240235 A1 PE 20240235A1 PE 2023002366 A PE2023002366 A PE 2023002366A PE 2023002366 A PE2023002366 A PE 2023002366A PE 20240235 A1 PE20240235 A1 PE 20240235A1
- Authority
- PE
- Peru
- Prior art keywords
- optionally substituted
- methyl
- compound
- membered
- 6alkyl
- Prior art date
Links
- -1 QUINAZOLINE COMPOUND Chemical class 0.000 title abstract 5
- 230000015556 catabolic process Effects 0.000 title abstract 2
- 238000006731 degradation reaction Methods 0.000 title abstract 2
- 102200006539 rs121913529 Human genes 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 4
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 abstract 3
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 3
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 abstract 2
- 229910052736 halogen Inorganic materials 0.000 abstract 2
- 150000002367 halogens Chemical class 0.000 abstract 2
- 125000000623 heterocyclic group Chemical group 0.000 abstract 2
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 2
- 229910052760 oxygen Inorganic materials 0.000 abstract 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 2
- 125000000843 phenylene group Chemical group C1(=C(C=CC=C1)*)* 0.000 abstract 2
- 229910052717 sulfur Inorganic materials 0.000 abstract 2
- 102100030708 GTPase KRas Human genes 0.000 abstract 1
- 101000584612 Homo sapiens GTPase KRas Proteins 0.000 abstract 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 abstract 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 abstract 1
- AAOVKJBEBIDNHE-UHFFFAOYSA-N diazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 abstract 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 abstract 1
- 125000001072 heteroaryl group Chemical group 0.000 abstract 1
- 125000005842 heteroatom Chemical group 0.000 abstract 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 1
- 125000001624 naphthyl group Chemical group 0.000 abstract 1
- 229910052757 nitrogen Inorganic materials 0.000 abstract 1
- 201000002528 pancreatic cancer Diseases 0.000 abstract 1
- 208000008443 pancreatic carcinoma Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- JWVCLYRUEFBMGU-UHFFFAOYSA-N quinazoline Chemical compound N1=CN=CC2=CC=CC=C21 JWVCLYRUEFBMGU-UHFFFAOYSA-N 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 229920006395 saturated elastomer Polymers 0.000 abstract 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 abstract 1
- 229920002554 vinyl polymer Polymers 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
La presente invencion se refiere a un compuesto derivado de quinazolina de formula (I), o una sal de este; en donde R1 es naftilo opcionalmente sustituido con OH o un grupo seleccionado de formulas (II) y (III); R1a y R1b, iguales o diferentes entre si, son H, metilo, F o Cl; R2 es H, halogeno, alquiloC1-3 opcionalmente sustituido, ciclopropilo o vinilo; R3 es un grupo heterociclico puenteado de 7 u 8 miembros saturado o insaturado, que contiene uno o dos atomos de N; R4 es alquiloC1-6, un grupo heterociclico saturado de 4 a 6 miembros, cada uno opcionalmente sustituidos, entre otros; R5 es alquiloC1-6 opcionalmente sustituido, cicloalquiloC3-6 opcionalmente sustituido, entre otros; R6a y R6b, iguales o diferentes entre si, son H o alquiloC1-6 opcionalmente sustituido, entre otros; R7 es H, halogeno, alquiloC1-3, -SO2CH3, cicloalquiloC3-6, entre otros; W es fenilo opcionalmente sustituido o heteroarilo de 6 miembros opcionalmente sustituido, que contiene uno a tres atomos de N, X es un enlace, CH2, O, S o NR4x; R4x es H o alquiloC1-3; Y es fenileno o piridindiilo, en donde el fenileno puede estar sustituido con F; L es -(L1-L2-L3-L4)-; en donde L es L1, L2, L3 y L4, iguales o diferentes entre si, son un grupo seleccionado de O, NRL1, pirrolidindiilo opcionalmente sustituido, piperidindiilo opcionalmente sustituido, entre otros; y Z es NH o heteroarendiilo de 5 miembros que contiene 1-4 heteroatomos seleccionados de O, S y N. Un compuesto seleccionado es (4R)-1-[(2S)-2-(4-{4-[({6-ciclopropil-4-[(1S,4S)-2,5-diazabiciclo[2.2.1]heptan-2-il]-7-(6-fluoro-5-metil-1H-indazol-4-il)-2-[(oxan-4-il)oxi]quinazolin-8-il}oxi)metil]fenil}-1H-1,2,3-triazol-1-il)-3-metilbutanoil]-4-hidroxi-N-{(1R)-2-hidroxi-1-[4-(4-metil-1,3-tiazol-5-il)fenil]etil}-L-prolinamida. Dicho compuesto induce la degradacion de la proteina KRAS mutante G12D. Tambien se refiere a metodos de preparacion de dicho compuesto y una composicion farmaceutica que lo comprende, siendo util en el tratamiento del cancer de pancreas.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021021656 | 2021-02-15 | ||
| PCT/JP2022/005582 WO2022173032A1 (ja) | 2021-02-15 | 2022-02-14 | Ｇ１２ｄ変異ｋｒａｓタンパクの分解を誘導するためのキナゾリン化合物 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20240235A1 true PE20240235A1 (es) | 2024-02-16 |
Family
ID=82838828
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2023002366A PE20240235A1 (es) | 2021-02-15 | 2022-02-14 | Compuesto de quinazolina para inducir la degradacion de la proteina kras mutante g12d |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US20240182483A1 (es) |
| EP (1) | EP4293024A1 (es) |
| JP (2) | JP7169729B1 (es) |
| KR (1) | KR20230145361A (es) |
| CN (1) | CN116848120A (es) |
| AR (1) | AR124870A1 (es) |
| AU (1) | AU2022221145A1 (es) |
| BR (1) | BR112023015067A2 (es) |
| CA (1) | CA3211051A1 (es) |
| CL (1) | CL2023002383A1 (es) |
| CO (1) | CO2023010710A2 (es) |
| CR (1) | CR20230404A (es) |
| DO (1) | DOP2023000161A (es) |
| EC (1) | ECSP23067156A (es) |
| IL (1) | IL305077A (es) |
| MX (1) | MX2023009521A (es) |
| PE (1) | PE20240235A1 (es) |
| TW (1) | TW202245751A (es) |
| WO (1) | WO2022173032A1 (es) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2023119677A1 (en) * | 2021-12-24 | 2023-06-29 | Astellas Pharma Inc. | Pharmaceutical composition comprising a quinazoline compound |
| WO2023171781A1 (ja) * | 2022-03-11 | 2023-09-14 | アステラス製薬株式会社 | Ｇ１２ｄ変異ｋｒａｓタンパクの分解を誘導するための複素環化合物 |
| WO2024029613A1 (ja) * | 2022-08-05 | 2024-02-08 | アステラス製薬株式会社 | 変異ｋｒａｓタンパクの分解を誘導するための複素環化合物 |
| WO2024034591A1 (ja) * | 2022-08-09 | 2024-02-15 | アステラス製薬株式会社 | Ｋｒａｓタンパクを阻害及び／又は分解誘導するための複素環化合物 |
| WO2024034593A1 (ja) * | 2022-08-09 | 2024-02-15 | アステラス製薬株式会社 | Ｇ１２ｖ変異ｋｒａｓタンパクの分解を誘導するための複素環化合物 |
| WO2024033537A1 (en) * | 2022-08-12 | 2024-02-15 | Astellas Pharma Inc. | Combination of anticancer agents comprising a bifunctional compound with g12d mutant kras inhibitory activity |
| WO2024033538A1 (en) * | 2022-08-12 | 2024-02-15 | Astellas Pharma Inc. | Combination of anticancer agents comprising a bifunctional compound with g12d mutant kras inhibitory activity |
| WO2024034123A1 (ja) * | 2022-08-12 | 2024-02-15 | アステラス製薬株式会社 | 複素環化合物を含む医薬組成物 |
| CN115873018B (zh) * | 2022-11-18 | 2024-03-15 | 中国药科大学 | 苯并嘧啶和苯并三嗪类造血祖细胞激酶1降解剂及其应用 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3608317A1 (en) | 2012-01-12 | 2020-02-12 | Yale University | Compounds & methods for the enhanced degradation of targeted proteins & other polypeptides by an e3 ubiquitin ligase |
| KR102320082B1 (ko) | 2014-04-14 | 2021-10-29 | 아비나스 오퍼레이션스, 인코포레이티드 | 단백질분해의 이미드-기초된 조절인자 및 연관된 이용 방법 |
| US10011600B2 (en) | 2014-09-25 | 2018-07-03 | Araxes Pharma Llc | Methods and compositions for inhibition of Ras |
| WO2016049565A1 (en) | 2014-09-25 | 2016-03-31 | Araxes Pharma Llc | Compositions and methods for inhibition of ras |
| US10822312B2 (en) | 2016-03-30 | 2020-11-03 | Araxes Pharma Llc | Substituted quinazoline compounds and methods of use |
| US10646488B2 (en) | 2016-07-13 | 2020-05-12 | Araxes Pharma Llc | Conjugates of cereblon binding compounds and G12C mutant KRAS, HRAS or NRAS protein modulating compounds and methods of use thereof |
| JOP20190186A1 (ar) * | 2017-02-02 | 2019-08-01 | Astellas Pharma Inc | مركب كينازولين |
| AU2019249231B2 (en) | 2018-04-04 | 2022-04-21 | Arvinas Operations, Inc. | Modulators of proteolysis and associated methods of use |
| US20210276996A1 (en) | 2018-07-20 | 2021-09-09 | Dana-Farber Cancer Institute, Inc. | Degraders that target proteins via keap1 |
| MX2022002465A (es) | 2019-08-29 | 2022-05-19 | Mirati Therapeutics Inc | Inhibidores de kras g12d. |
| TW202124374A (zh) | 2019-09-13 | 2021-07-01 | 美商拜歐斯瑞克斯公司 | Ras蛋白降解劑、其醫藥組合物及其治療應用 |
| WO2021106231A1 (en) | 2019-11-29 | 2021-06-03 | Taiho Pharmaceutical Co., Ltd. | A compound having inhibitory activity against kras g12d mutation |
-
2022
- 2022-02-14 CN CN202280014815.8A patent/CN116848120A/zh active Pending
- 2022-02-14 CR CR20230404A patent/CR20230404A/es unknown
- 2022-02-14 JP JP2022542202A patent/JP7169729B1/ja active Active
- 2022-02-14 AR ARP220100290A patent/AR124870A1/es unknown
- 2022-02-14 KR KR1020237027669A patent/KR20230145361A/ko unknown
- 2022-02-14 AU AU2022221145A patent/AU2022221145A1/en active Pending
- 2022-02-14 PE PE2023002366A patent/PE20240235A1/es unknown
- 2022-02-14 TW TW111105240A patent/TW202245751A/zh unknown
- 2022-02-14 WO PCT/JP2022/005582 patent/WO2022173032A1/ja active Application Filing
- 2022-02-14 US US18/268,001 patent/US20240182483A1/en active Pending
- 2022-02-14 MX MX2023009521A patent/MX2023009521A/es unknown
- 2022-02-14 CA CA3211051A patent/CA3211051A1/en active Pending
- 2022-02-14 EP EP22752854.4A patent/EP4293024A1/en active Pending
- 2022-02-14 IL IL305077A patent/IL305077A/en unknown
- 2022-02-14 BR BR112023015067A patent/BR112023015067A2/pt unknown
- 2022-10-27 JP JP2022172197A patent/JP2022191505A/ja active Pending
-
2023
- 2023-08-11 CL CL2023002383A patent/CL2023002383A1/es unknown
- 2023-08-15 DO DO2023000161A patent/DOP2023000161A/es unknown
- 2023-08-16 CO CONC2023/0010710A patent/CO2023010710A2/es unknown
- 2023-09-05 EC ECSENADI202367156A patent/ECSP23067156A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA3211051A1 (en) | 2022-08-18 |
| ECSP23067156A (es) | 2023-10-31 |
| CL2023002383A1 (es) | 2024-01-19 |
| EP4293024A1 (en) | 2023-12-20 |
| JPWO2022173032A1 (es) | 2022-08-18 |
| KR20230145361A (ko) | 2023-10-17 |
| WO2022173032A1 (ja) | 2022-08-18 |
| US20240182483A1 (en) | 2024-06-06 |
| MX2023009521A (es) | 2023-08-24 |
| AR124870A1 (es) | 2023-05-17 |
| IL305077A (en) | 2023-10-01 |
| CR20230404A (es) | 2023-09-21 |
| TW202245751A (zh) | 2022-12-01 |
| JP2022191505A (ja) | 2022-12-27 |
| BR112023015067A2 (pt) | 2023-10-03 |
| CO2023010710A2 (es) | 2023-09-18 |
| AU2022221145A1 (en) | 2023-09-21 |
| CN116848120A (zh) | 2023-10-03 |
| JP7169729B1 (ja) | 2022-11-11 |
| DOP2023000161A (es) | 2023-09-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20240235A1 (es) | Compuesto de quinazolina para inducir la degradacion de la proteina kras mutante g12d | |
| PE20230161A1 (es) | Inhibidores de proteinas kras mutantes | |
| RU2481336C2 (ru) | Циклопента(d)пиримидины в качестве ингибиторов протеинкиназ акт | |
| AR054214A1 (es) | Compuestos derivados de 1, 1 - dioxotiadiazina, composiciones farmaceuticas que los contienen y su uso en el tratamiento de la infeccion por el virus de la hepatitis c. | |
| EA200400953A1 (ru) | Замещённые пиридиноны в качестве модуляторов map-киназы p38 | |
| AR045595A1 (es) | Composiciones utiles como inhibidores de proteinas quinasas | |
| CO5570663A2 (es) | Derivados del acido mandelico | |
| AR079541A1 (es) | Compuestos sustituidos de n-(1h-indazol-4-il) imidazo (1,2-a) piridin-3-carboxamida como inhibidores de cfms | |
| PE20020854A1 (es) | SULFONAMIDA LACTAMA COMO INHIBIDORES DEL FACTOR Xa | |
| PE20080677A1 (es) | Inhibidores de pirrolotriazina cinaza | |
| AR056691A1 (es) | Derivados pirrolopirimidina como inhibidores de syk | |
| PE20040999A1 (es) | Nuevas pirazolopirimidinas como inhibidores de cinasas dependientes de ciclinas | |
| RU2015112192A (ru) | 2-оксо-2,3,4,5-тетрагидро-1н-бензо[b]диазепины и их применение при лечении рака | |
| EA200400073A1 (ru) | Пирролопиримидины как ингибиторы протеинкиназы | |
| AR076860A1 (es) | Derivados de 7-aril- 1,2,4-triazolo[4,3-a]piridina moduladores alostericos positivos de receptores mglur2, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de trastornos neurologicos y siquiatricos. | |
| AR063099A1 (es) | Compuestos y composiciones como inhibidores de la proteina quinasa | |
| AR047557A1 (es) | Compuestos derivados de piridazina y su uso como agentes terapeuticos | |
| PE20211703A1 (es) | Compuesto derivado heterotriciclico novedoso y uso del mismo | |
| PE20071061A1 (es) | Derivados de carbonilo como inhibidores de peptidil-deformilasa (pdf) | |
| PE20220139A1 (es) | Compuestos de tioeno[3,2-b] piridin-7-amina para tratar la disautonomia familiar | |
| PE20212247A1 (es) | Compuestos de 3-((3-aminofenil)amino)piperidina-2,6-diona sustituida, composiciones de estos y metodos de tratamiento con estos | |
| RU2008130111A (ru) | (индазол-5-ил)пиразины и (1,3-дигидроиндол-2-он)пиразины для лечения опосредованнызх rно-киназой заболеваний и состояний | |
| AR057981A1 (es) | Compuesto de pirroloquinolin -4- ona, su uso para la preparacion de un medicamento, composicion farmaceutica que lo comprende y compuestos intermediarios pra su preparacion | |
| AR055321A1 (es) | Compuestos de imidazopiridina uso para a fabricacion de un medicamento para el tratamiento o profilaxis de enfermedades o trastornos en los que se requiere un antagonista de una bomba de acido y composicion farmaceutica que lo comprende | |
| AR080032A1 (es) | Compuestos de pirazol como antagonistas de crth2 |